Making early disease detection possible
Veravas is transforming how patient samples are collected and processed enabling healthcare professionals and clinicians to predict and diagnose early-stage disease more accurately.
THE PROBLEM
Challenges in Test Accuracy
Interferences in a patient sample can significantly impact the results of an assay by introducing inaccuracies, false positives, or false negatives. To overcome their impact, assay developers and laboratories may employ strategies intended to minimize the effects and compensate for known interferences. Assay interference can affect result outcomes in several ways:
False Positives
indicates the presence of a particular disease, condition or analyte when it is not actually present.
False Negatives
When the assay fails to detect the presence of the disease, condition or target analyte.
Heterophilic Interference
Can impact immunoassay signal response and deliver false test results.
Matrix Effects
Can introduce biological noise, impact limit of detection and increase variability of test results.
THE SOLUTION
VERAVAS' VeraBIND Enhances Biomarker Detection
The sample collection stage is the optimal point to eliminate these interferences. Veravas' VeraBIND™ technology transforms the original sample into a standardized, matrix-free sample that laboratories can analyze using existing equipment and without adding time to result.
VeraBIND, specifically designed for clinical diagnostics and research, enables the detection of low abundance or previously elusive biomarkers with enhanced sensitivity. Once validated, it seamlessly integrates with commercially available assays and can be utilized with various detection methods, such as ELISA, chemiluminescence, and mass spectrometry.
Challenges of Diagnosing Alzheimer's Disease
Navigating the diagnostic landscape of Alzheimer's disease presents a multitude of challenges.
Without a singular, definitive test, distinguishing it from other dementias becomes a complex task due to overlapping symptoms. Early detection is another hurdle, as the initial, subtle signs are often overlooked as part of the natural aging process, and cognitive assessments can be influenced by an individual's background and mental state.
Moreover, the variability in disease introduces further complexity in effectively managing and monitoring the condition. The financial and logistical barriers associated with obtaining a comprehensive diagnostic evaluation underscore the critical need for innovation in this area.
Veravas is excited to apply its VeraBIND technology to help improve the precision, accessibility, and affordability of Alzheimer's diagnostics, aiming to better navigate this challenging landscape.
Challenges of Diagnosing Alzheimer's Disease
Navigating the diagnostic landscape of Alzheimer's disease presents a multitude of challenges.
Without a singular, definitive test, distinguishing it from other dementias becomes a complex task due to overlapping symptoms. Early detection is another hurdle, as the initial, subtle signs are often overlooked as part of the natural aging process, and cognitive assessments can be influenced by an individual's background and mental state.
Moreover, the variability in disease introduces further complexity in effectively managing and monitoring the condition. The financial and logistical barriers associated with obtaining a comprehensive diagnostic evaluation underscore the critical need for innovation in this area.
Veravas is excited to apply its VeraBIND technology to help improve the precision, accessibility, and affordability of Alzheimer's diagnostics, aiming to better navigate this challenging landscape.
Challenges of Diagnosing Alzheimer's Disease
Navigating the diagnostic landscape of Alzheimer's disease presents a multitude of challenges.
Without a singular, definitive test, distinguishing it from other dementias becomes a complex task due to overlapping symptoms. Early detection is another hurdle, as the initial, subtle signs are often overlooked as part of the natural aging process, and cognitive assessments can be influenced by an individual's background and mental state.
Moreover, the variability in disease introduces further complexity in effectively managing and monitoring the condition. The financial and logistical barriers associated with obtaining a comprehensive diagnostic evaluation underscore the critical need for innovation in this area.
Veravas is excited to apply its VeraBIND technology to help improve the precision, accessibility, and affordability of Alzheimer's diagnostics, aiming to better navigate this challenging landscape.
Who is Veravas
Veravas is reshaping the landscape of assay development and biomarker detection, setting a new standard in clinical diagnostics and research. Through improved accuracy and streamlined workflows, together we can anticipate better outcomes and an enhanced quality of life for patients worldwide.
Sign up to receive regular updates from Veravas, including press releases, product updates, and industry events.
We value your privacy